To assess whether TTR macrophages at baseline could be used as a predictive marker for response, we used a tissue microarray (TMA) of a melanoma cohort of baseline tumors from patients who responded or acquired resistance after BRAFi/MEKi treatment (cohort 4, Figure 5A; Table S1). Here, TTR is linked to melanoma.